Johnson & Johnson pauses COVID-19 vaccine trial after US recommends investigation of rare clotting reports
By Kelly Hayes
U.S. officials recommend ‘pause’ of J&J vaccine
In a joint statement, the CDC and the FDA said it was investigating clots in six women in the days after vaccination, in combination with reduced platelet counts.
WASHINGTON - Johnson & Johnson said it will pause its ongoing vaccine trial after federal health officials on Tuesday recommended a pause on the use of its COVID-19 vaccine in order to investigate reports in the U.S. of a rare type of blood clotting following vaccination.
The CDC’s Advisory Committee on Immunization Practices on Wednesday will review data on six cases of blood clotting. Nearly 7 million J&J doses have been administered in the U.S., the vast majority experiencing no or mild side effects.
White House now admits the number of daily vaccinations WILL be affected after pause of J&J shot despite shipments of Pfizer and Moderna COVID-19 vaccines increasing by 7% next week
The U.S. government is increasing its allocations of the Pfizer-BioNTech and Moderna coronavirus vaccine by 7% next week compared to this week
More than 10 million first and second doses of the Pfizer vaccine will be shipped, an increase from 9.4 million during the week of April 12
In addition, 7.4 million initial and final doses of Moderna s vaccine will be sent to states and jurisdictions the week of April 19, up from 6.9 million
It comes as the CDC and FDA recommended that sites across the country pause using the J&J vaccine after six reports of rare, but serious, blood clots
CDC advisory panel to hold emergency meeting Wednesday over J&J COVID-19 vaccine fox13news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fox13news.com Daily Mail and Mail on Sunday newspapers.